Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.33 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.33 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.33 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1168662 | 0.98 | LTA4H (0.35) | L3MBTL1MEN1KMT2ATDP1LTA4H | |
| SCHEMBL27499418 | 0.96 | LTA4H (0.38) | L3MBTL1LTA4HALDH1A1HRH3GNAI3 | |
| SCHEMBL2106033 | 0.96 | LTA4H (0.38) | L3MBTL1LTA4HALDH1A1HRH3GNAI3 | |
| SCHEMBL6506199 | 0.94 | L3MBTL1 (0.33) | L3MBTL1MEN1KMT2ATDP1LTA4H | |
| SCHEMBL2099498 | 0.92 | CYP1A2 (0.34) | L3MBTL1MEN1KMT2ATDP1LTA4H | |
| SCHEMBL1081166 | 0.92 | ALDH1A1 (0.36) | L3MBTL1MEN1KMT2ALTA4HALDH1A1 | |
| SCHEMBL294888 | 0.90 | GNAI3 (0.38) | LTA4HALDH1A1GNAI3GNAO1GNAI1 | |
| SCHEMBL9167013 | 0.90 | GNAI3 (0.38) | LTA4HALDH1A1GNAI3GNAO1GNAI1 | |
| SCHEMBL4914244 | 0.85 | — | — | |
| SCHEMBL607241 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004056353-A2 | DEVICE AND METHOD FOR DELIVERING MMP INHIBITORS | NOVARTIS AG (CH) | 2004-07-08 | — | — | WO | claimed |
| EP-0766672-B1 | ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | NOVARTIS AG (CH) | 2000-10-04 | — | — | EP | claimed |
| EP-0766672-A1 | ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | Novartis AG (CH) | 1997-04-09 | — | — | EP | claimed |
| WO-1996040101-A1 | CERTAIN ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACIDS FOR THE TREATMENT OF CERTAIN TUMORS | NOVARTIS AG (CH) | 1996-12-19 | — | — | WO | claimed |
| US-5552419-A | METALLOPROTEINASE INHIBITORS | CIBA-GEIGY CORPORATION (US) | 1996-09-03 | — | — | US | claimed |
| US-5506242-A | METALLOELASTASE INHIBITOR; TREATS EMPHYSEMA | CIBA-GEIGY CORPORATION (US) | 1996-04-09 | — | — | US | claimed |
| WO-1996000214-A1 | ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | CIBA-GEIGY AG (CH) | 1996-01-04 | — | — | WO | claimed |
| WO-2005082892-A2 | TRIAZOLE COMPOUNDS AS ANTIBACTERIAL AGENTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S LABORATORIES LTD. (IN) | 2005-09-09 | — | — | WO | disclosed |
| WO-2004056353-A2 | DEVICE AND METHOD FOR DELIVERING MMP INHIBITORS | NOVARTIS AG (CH) | 2004-07-08 | — | — | WO | disclosed |
| EP-0766672-B1 | ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | NOVARTIS AG (CH) | 2000-10-04 | — | — | EP | disclosed |
| US-5672615-A | MATRIX-DEGRADING METALLOPROTEINASE INHIBITORS | NOVARTIS CORPORATION (US) | 1997-09-30 | — | — | US | disclosed |
| US-5646167-A | ADMINISTERED AS METALLOPROTEINASE INHIBITOR, ANTITUMOR OR ANTICARCINOGENIC AGENT | CIBA-GEIGY CORPORATION (US) | 1997-07-08 | — | — | US | disclosed |
| EP-0766672-A1 | ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | Novartis AG (CH) | 1997-04-09 | — | — | EP | disclosed |
| WO-1996040101-A1 | CERTAIN ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACIDS FOR THE TREATMENT OF CERTAIN TUMORS | NOVARTIS AG (CH) | 1996-12-19 | — | — | WO | disclosed |
| US-5552419-A | METALLOPROTEINASE INHIBITORS | CIBA-GEIGY CORPORATION (US) | 1996-09-03 | — | — | US | disclosed |
| US-5506242-A | METALLOELASTASE INHIBITOR; TREATS EMPHYSEMA | CIBA-GEIGY CORPORATION (US) | 1996-04-09 | — | — | US | disclosed |
| WO-1996000214-A1 | ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS | CIBA-GEIGY AG (CH) | 1996-01-04 | — | — | WO | disclosed |